HiPlas™ LentiHelper Plasmids for T

Advantages of HiPlas™ LentiHelper Plasmids for T

Spectrum Biotech’s proprietary four-plasmid vector system ensures compliance and traceability in plasmid production while efficiently supporting lentiviral packaging. It demonstrates exceptional infection efficiency even at low MOI levels in T cells.

• Off-the-shelf plasmids: GMP-grade off-the-shelf plasmids that meet the needs of projects at various stages;

• The four-plasmid vector system significantly reduces the likelihood of RCL formation, enhancing the safety of the vector system;

• Includes a modified WPRE element, which enhances target gene expression while ensuring safety (the modified WPRE is highlighted);

• Utilizes the Kana resistance gene, the only compliant option for marketed cell therapies;

• Optimizes potentially oncogenic sequences (the modified wild-type WPRE element expresses a truncated version of the X-protein sequence, thereby mitigating the risk of cancer);

• Optimized promoter selection that balances efficiency and safety;

• Upon obtaining a DMF registration number, the system can be directly incorporated into FDA IND submissions, providing comprehensive pharmaceutical research data;

• IND submission materials for the three auxiliary plasmids have assisted multiple global CAR-T, TCR-T, and other cell therapy products in obtaining implied clinical trial approval.

Details of HiPlas™ LentiHelper Plasmids for T